TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. (TCRX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -40,926,000 | 121.28 M | 272.15 M | 194.24 M | |
| 2022 | -34,043,000 | 99.66 M | 199.09 M | 120.03 M | |
| 2021 | -155,362,000 | 27.33 M | 188.11 M | 165.65 M | |
| 2020 | -27,357,000 | 92.2 M | 49.74 M | 36.45 M | |
| 2019 | -36,877,000 | 66.52 M | 49.38 M | 42.38 M |